share_log

HC Wainwright & Co. Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $15

HC Wainwright & Co. Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $15

HC Wainwright & Co.维持对Aurinia Pharmicals的买入,将目标股价提高至15美元
Benzinga ·  2023/08/07 12:02

HC Wainwright & Co. analyst Ed Arce maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and raises the price target from $14 to $15.

HC Wainwright&Co.分析师埃德·阿尔斯维持金光制药(纳斯达克:AUPH)的买入,并将目标价从14美元上调至15美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发